StemCells said the restructuring will support the growth of the stem cell culture and cell-based assay platforms it inherited as part of its estimated $4.8 million acquisition of SCS in April.
The $4.4 million acquisition provides StemCells with cell-based drug discovery technologies.
News in brief
SCS' shareholders voted in favor of the nearly $5 million deal.
StemCells plans to invest in Stem Cell Sciences' operational facilities in Cambridge, UK, in order to provide cell-based assay services to the drug discovery industry there, according to SCS' CEO.
StemCells, which is focused on developing tissue-derived cellular products for therapeutic uses, gains cell-based drug discovery technologies through the $4.8 million deal.
The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.
In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.